177 related articles for article (PubMed ID: 30798670)
21. Dolutegravir-Rilpivirine, Dual Antiretroviral Therapy for the Treatment of HIV-1 Infection.
Hester EK; Astle K
Ann Pharmacother; 2019 Aug; 53(8):860-866. PubMed ID: 30758229
[No Abstract] [Full Text] [Related]
22. New Dual Combination of Dolutegravir-Rilpivirine for Switching to Maintenance Antiretroviral Therapy.
Ribera E
AIDS Rev; 2018; 20(4):179-186. PubMed ID: 30548024
[TBL] [Abstract][Full Text] [Related]
23. Emergence of dual antiretroviral therapy as a viable regimen option for the treatment of patients with HIV infection.
Fida M; Mahmood M; Temesgen Z
Drugs Today (Barc); 2020 Jun; 56(6):405-421. PubMed ID: 32525138
[TBL] [Abstract][Full Text] [Related]
24. Changes in functional connectivity in people with HIV switching antiretroviral therapy.
Toniolo S; Cercignani M; Mora-Peris B; Underwood J; Alagaratnam J; Bozzali M; Boffito M; Nelson M; Winston A; Vera JH
J Neurovirol; 2020 Oct; 26(5):754-763. PubMed ID: 32500477
[TBL] [Abstract][Full Text] [Related]
25. Raltegravir dosage adjustment in HIV-infected patients receiving etravirine.
Do VT; Higginson RT; Fulco PP
Am J Health Syst Pharm; 2011 Nov; 68(21):2049-54. PubMed ID: 22011983
[TBL] [Abstract][Full Text] [Related]
26. Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance.
Malet I; Thierry E; Wirden M; Lebourgeois S; Subra F; Katlama C; Deprez E; Calvez V; Marcelin AG; Delelis O
J Antimicrob Chemother; 2015 Oct; 70(10):2870-80. PubMed ID: 26205139
[TBL] [Abstract][Full Text] [Related]
27. A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data.
Capetti AF; Cossu MV; Orofino G; Sterrantino G; Cenderello G; De Socio GV; Cattelan AM; Soria A; Rusconi S; Riccardi N; Baldin GM; Niero FP; Barbarini G; Rizzardini G
BMC Infect Dis; 2017 Sep; 17(1):658. PubMed ID: 28964268
[TBL] [Abstract][Full Text] [Related]
28. Addition of Etravirine Does Not Enhance the Initial Decline of HIV-1 RNA in Treatment-Experienced Patients Receiving Raltegravir.
Flandre P; Marcelin AG; Calvez V;
J Acquir Immune Defic Syndr; 2017 Aug; 75(4):448-454. PubMed ID: 28653971
[TBL] [Abstract][Full Text] [Related]
29. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
Cohen CJ; Andrade-Villanueva J; Clotet B; Fourie J; Johnson MA; Ruxrungtham K; Wu H; Zorrilla C; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
Lancet; 2011 Jul; 378(9787):229-37. PubMed ID: 21763935
[TBL] [Abstract][Full Text] [Related]
30. Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patients.
Casado JL; Vizcarra P; Blanco JL; Montejano R; Negredo E; Espinosa N; Montero M; Mena A; Palacios R; Lopez JC; Vergas J; Galindo MJ; Cabello A; Deltoro MG; Diaz De Santiago A;
Int J STD AIDS; 2020 Apr; 31(5):467-473. PubMed ID: 32138618
[No Abstract] [Full Text] [Related]
31. Alternative switching strategies based on regimens with a low genetic barrier: do clinicians have a choice nowadays?
Troya J; Ryan P; Montejano R; Cabello A; Cuevas G; Matarranz M; Cañamares I; Solís J; Walther LÁ
Eur J Clin Microbiol Infect Dis; 2019 Mar; 38(3):423-426. PubMed ID: 30443683
[TBL] [Abstract][Full Text] [Related]
32. Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort.
Capetti AF; Sterrantino G; Cossu MV; Cenderello G; Cattelan AM; De Socio GV; Rusconi S; Riccardi N; Baldin GM; Cima S; Niero FP; Rizzardini G; Sasset L
Antivir Ther; 2017; 22(3):257-262. PubMed ID: 27661787
[TBL] [Abstract][Full Text] [Related]
33. Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study.
Lê MP; Valantin MA; Assoumou L; Soulie C; Le Mestre S; Weiss L; Yazdanpanah Y; Molina JM; Bouchaud O; Raffi F; Reynes J; Calvez V; Marcelin AG; Costagliola D; Katlama C; Peytavin G;
Pharmacotherapy; 2019 Apr; 39(4):514-520. PubMed ID: 30815916
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis.
Merli M; Galli L; Marinaro L; Ariaudo A; Messina E; Uberti-Foppa C; Castagna A; D'Avolio A; Lazzarin A; Bonora S; Hasson H
J Antimicrob Chemother; 2017 Mar; 72(3):812-815. PubMed ID: 27999010
[TBL] [Abstract][Full Text] [Related]
35. Dual Raltegravir-Etravirine Combination as Maintenance Regimen in Virologically Suppressed HIV-1-Infected Patients.
Calza L; Magistrelli E; Colangeli V; Manfredi R; Borderi M; Rossi N; Conti M; Mancini R; Viale P
AIDS Res Hum Retroviruses; 2017 Jul; 33(7):632-638. PubMed ID: 28088884
[TBL] [Abstract][Full Text] [Related]
36. A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients.
Ciccullo A; Baldin G; Capetti A; Rusconi S; Sterrantino G; d'Ettorre G; Colafigli M; Modica S; Lagi F; Giacomelli A; Cossu MV; Restelli S; De Luca A; Di Giambenedetto S
Antivir Ther; 2019; 24(1):63-67. PubMed ID: 30277466
[TBL] [Abstract][Full Text] [Related]
37. Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen.
Armenia D; Di Carlo D; Calcagno A; Vendemiati G; Forbici F; Bertoli A; Berno G; Carta S; Continenza F; Fedele V; Bellagamba R; Cicalini S; Ammassari A; Libertone R; Zaccarelli M; Ghisetti V; Andreoni M; Ceccherini-Silberstein F; Bonora S; Di Perri G; Antinori A; Perno CF; Santoro MM
J Antimicrob Chemother; 2017 Mar; 72(3):855-865. PubMed ID: 27999048
[TBL] [Abstract][Full Text] [Related]
38. Dolutegravir/Rilpivirine: A Review in HIV-1 Infection.
Blair HA
Drugs; 2018 Nov; 78(16):1741-1750. PubMed ID: 30406902
[TBL] [Abstract][Full Text] [Related]
39. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
[TBL] [Abstract][Full Text] [Related]
40. Association of dolutegravir and rilpivirine, enhanced by foscarnet induction, in effective salvage antiretroviral therapy.
Leporrier J; Etienne M; Chapuzet C; Peytavin G; Bord S; Borsa-Lebas F; Caron F; Plantier JC; Mourez T
J Clin Virol; 2014 Aug; 60(4):428-30. PubMed ID: 24932736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]